Peregrine Pharma RELEASES Study Results and 4 Stocks Reaching 52-Week Highs

Lender Processing (NYSE:LPS) has announced that LPS President and Chief Executive Officer Hugh Harris was diagnosed with a treatable form of cancer. On August 31, Harris underwent a surgical procedure for the removal of a tumor from his neck, discovered during a routine annual physical examination. Harris is to continue in his role while undergoing several post-operative treatments, although during his treatments, particular day-to-day responsibilities are to be assumed by the other senior members of the executive management team. Based on the current outlook for his treatment, Harris shoul make a full recovery. The shares closed at $28.54, down $0.19 or 0.66% on the day. They have traded in a 52-week range of $12.91 to $29.03.

News Corp. (NASDAQ:NWSA): U.S. District Judge Denise Cote in Manhattan has approved a settlement with three major book publishers regarding the alleged collusion in e-book pricing, according to the Wall Street Journal. In April, Lagardre SCA’s Hachette Book Group, CBS’s (NYSE:CBS) Simon & Schuster and News Corp.’s HarperCollins Publishers agreed as part of the settlement to end their agreements with Apple (NASDAQ:AAPL) and keep from limiting any retailer’s ability to set e-book prices for two years. The shares closed at $24.47, down $0.03 or 0.12% on the day. They have traded in a 52-week range of $14.72 to $24.54.

Penske Automotive (NYSE:PAG): Shapiro Capital reports a 4.64 percent passive stake in Penske Automotive. The shares closed at $28.79, up $0.29 or 1.02% on the day. They have traded in a 52-week range of $14.87 to $28.52.

Peregrine Pharmaceut (NASDAQ:PPHM) announced that interim results have been presented from its 121 patient randomized, double-blind, placebo-controlled Phase IIb trial in patients with refractory non-small cell lung cancer, and the blinded study evaluated two dose levels of bavituximab that was given with docetaxel versus docetaxel plus placebo. The interim data indicated a statistically significant improvement in the overall survival and a doubling of median overall survival in the bavituximab-containing arms versus the control arm. The interim results from the study indicated no significant safety differences between the three treatment arms as determined by the trial’s independent data monitoring committee. The shares closed at $4.50, up $1.43 or 46.58% on the day. They have traded in a 52-week range of $0.39 to $3.25.

U.S. Bancorp (NYSE:USB): A key interest rate for over $500 trillion of securities globally is to be replaced by a benchmark subject to greater government control, according to 45 percent of people responding to a quarterly Bloomberg Global Poll. They stated that the London interbank offered rate, known as Libor, is to be supplanted by a more regulated model within five years, according to Bloomberg. The shares closed at $33.98, up $0.05 or 0.15% on the day. They have traded in a 52-week range of $21.53 to $34.10.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>